Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Morgan Bowen

Clinical Nurse Specialist, Psychiatric/Mental Health, Adult Mason, MI Nurse Practitioner

NPI 1003410697 CMS profile 11135294

806 Hogsback Rd Ste C, Mason, MI 48854

Open in the dashboard

General payments

$3,959

194 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Morgan Bowen of Mason, MI is reported in the CMS Open Payments database as having received $3,959 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $877 40
2024 General $531 27
2023 General $475 20
2022 General $1,228 59
2021 General $849 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Morgan Bowen
  • Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Morgan Bowen were reported at $877. Among 197 Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles paid that year, the median was $174 and the middle half received between $71 and $653.

Show as a table
Year Morgan Bowen Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $849 $152 $38–$472 $132
2022 $1,228 $172 $73–$546 $149
2023 $475 $156 $56–$560 $160
2024 $531 $158 $39–$521 $164
2025 $877 $174 $71–$653 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Pharmaceuticals, Inc $568 24 payments
  2. Alkermes, Inc. $494 17 payments
  3. AbbVie, Inc. $423 33 payments
  4. ITI, Inc. $358 17 payments
  5. Teva Pharmaceuticals USA, Inc. $351 17 payments
  6. Otsuka America Pharmaceutical, Inc. $339 18 payments
  7. Neurocrine Biosciences, Inc. $299 15 payments
  8. Corium, Inc. $248 12 payments
  9. Lundbeck LLC $188 9 payments
  10. Jazz Pharmaceuticals Inc. $166 4 payments
  11. Other $527 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,959 194 payments
Products named General payments · program years 2021–2025
  1. SPRAVATO $502 21 payments
  2. LYBALVI Cns $494 17 payments
  3. ARISTADA Cns $384 16 payments
  4. ARISTADA Cns $384 16 payments
  5. VRAYLAR $376 30 payments
  6. LYBALVI Cns $324 11 payments
  7. CAPLYTA $324 15 payments
  8. REXULTI $295 16 payments
  9. INGREZZA $277 14 payments
  10. Austedo XR $256 12 payments
  11. Other $2,459 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

114

Median for Nurse Practitioner: 389

Drug cost

$22,159

Median for Nurse Practitioner: $21,885

Branded share of claims

34.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 14 $20,363
Bupropion Xl Bupropion Hcl Brand 14 $564
Buspirone Hcl Generic 19 $442
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 11 $323
Sertraline Hcl Generic 12 $190
Clonazepam Generic 30 $141
Trazodone Hcl Generic 14 $136

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
  • Corium, Inc. $118
$118 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $101
$101 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $87
$87 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $36
  • Lundbeck LLC $35
$71 — —
VRAYLAR
  • AbbVie, Inc. $60
$60 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health, Adult in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record